Iridium( iii )/rhenium( i ) complexes bearing NLG919 as the ligand for enhanced triple-negative breast cancer therapy
Dalton Transactions · 2025 · 54 (39) · 14962-14968
DOI: 10.1039/d5dt01732g ↗Kurz gefasst
Fachartikel in der Zeitschrift Dalton Transactions, 2025. Verfasst von Hou Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, P. R. China. yerr@mail2.sysu.edu.cn. Hauptthemen laut MEDLINE: Iridium, Rhenium, Coordination Complexes, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Four novel iridium( iii )/rhenium( i )-NLG919 complexes exhibited excellent anti-tumor activity against 4T1 cells and induced cell death by inhibiting IDO expression, suppressing cell proliferation, inducing apoptosis, and triggering ICD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, P. R. China. yerr@mail2.sysu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhu, H., Yang, Y. S., Zhu, L. Y., Jiang, C. R., Zhang, Z., Xu, M. T., Li, R. T., & Ye, R. R. (2025). Iridium( iii )/rhenium( i ) complexes bearing NLG919 as the ligand for enhanced triple-negative breast cancer therapy. Dalton Transactions, 54(39), 14962-14968. https://doi.org/10.1039/d5dt01732g
Vancouver
Zhu H, Yang YS, Zhu LY, Jiang CR, Zhang Z, Xu MT, et al. Iridium( iii )/rhenium( i ) complexes bearing NLG919 as the ligand for enhanced triple-negative breast cancer therapy. Dalton Transactions. 2025;54(39):14962-14968. doi:10.1039/d5dt01732g
BibTeX
@article{Zhu2025,
author = {Zhu, Hou and Yang, Yong-Sheng and Zhu, Lin-Yuan and Jiang, Chun-Rong and Zhang, Zheng and Xu, Meng-Ting and Li, Rong-Tao and Ye, Rui-Rong},
title = {Iridium( iii )/rhenium( i ) complexes bearing NLG919 as the ligand for enhanced triple-negative breast cancer therapy},
journal = {Dalton Transactions},
year = {2025},
volume = {54},
number = {39},
pages = {14962--14968},
doi = {10.1039/d5dt01732g}
}
EUVIMED